美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物科技指數ETF-iShares Nasdaq

216.40

+3.871.82%

盤後：216.38-0.0200-0.01%18:22 EDT

成交量：146.61萬

成交額：3.17億

市值：108.85億

市盈率：34.28

高：217.12

開：213.40

低：213.22

收：212.53

52周最高：217.12

52周最低：137.09

股本：5,030.00萬

流通股本：5,030.00萬

量比：0.69

換手率：2.91%

股息：0.40

股息率：0.19%

每股收益(TTM):6.31

每股收益(LYR):-1.4940

淨資產收益率：24.54%

總資產收益率：0.10%

市淨率：1.34

市盈率(LYR):-144.85

資料載入中...

總覽公司新聞資訊公告

EyePoint公司治療年齡相關性眼病的藥物晚期臨床試驗失敗，股價暴跌

美股異動 | Argenx(ARGX.US)盤前升逾10% 自身免疫性肌炎藥物Vyvgart III期研究達主要終點

美股異動丨Argenx SE盤前大升逾7%，Efgartigimod治療肌炎III期試驗成功

復星醫藥子公司攜生物類似藥出海牽手全球仿製藥龍頭，鎖定四成銷售分成

每日经济新闻

復宏漢霖與山德士達成戰略合作

argenx SE（ARGX）宣佈Efgartigimod治療自身免疫性肌炎的3期ALKIVIA試驗取得積極結果

巴克萊上調安進目標價至380美元

復宏漢霖擬向山德士授權至多10款生物類似藥，國產生物藥國際化再進一步｜醫藥早參

每日经济新闻

復宏漢霖攜手Sandoz佈局生物類似藥首批3款產品落地

復星醫藥：控股子公司與Sandoz AG達成至多10款生物類似藥許可合作，首批3款產品首付款及里程碑款至多2.37億美元

Assembly股價上漲，因季度營收超出預期

中國銀河證券：實驗動物為創新藥研發剛需小鼠+猴雙主線高景氣

百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務不涉及創新藥研發

MacroGenics股價上漲，因吉利德支付了1000萬美元的里程碑款項

數據簡報-全球製藥企業斥資數十億以擴大在美業務

Tango因季度虧損額超出預期而股價下跌

百花醫藥(600721.SH)：不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

東方證券：AI重構創新藥研發底座國內相關產業鏈公司亦有望受益

百濟神州（06160）盤初漲3.94% 與安進聯合開發及商業化的安泰適正式投入臨床使用

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/IBB/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指數ETF-iShares Nasdaq","latestPrice":216.4,"timestamp":1787688000000,"preClose":212.53,"halted":0,"volume":1466073,"hourTrading":{"tag":"盘后","latestPrice":216.38,"preClose":216.4,"latestTime":"18:22 EDT","volume":19582,"amount":4237546.7582,"timestamp":1787696558762,"change":-0.02,"changeRate":-0.000092,"amplitude":0.01079},"delay":0,"changeRate":0.018209193996141744,"floatShares":50300000,"shares":50300000,"eps":6.311863,"marketStatus":"盤後交易","change":3.87,"latestTime":"08-25 18:53:01 EDT","open":213.4,"high":217.12,"low":213.22,"amount":316778454.13221,"amplitude":0.01835,"askPrice":217.51,"askSize":1,"bidPrice":216.01,"bidSize":1400,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":212.53,"sharesOutstanding":49450000,"nav":213.623549,"aum":10681177450,"dividendRate":0.001866,"bidAskSpread":0.000342,"preHourTrading":{"tag":"盘前","latestPrice":213.19,"preClose":212.53,"latestTime":"09:29 EDT","volume":272,"amount":58020.02352,"timestamp":1787664595037,"change":0.66,"changeRate":0.003105,"amplitude":0.007293},"postHourTrading":{"tag":"盘后","latestPrice":216.38,"preClose":216.4,"latestTime":"18:22 EDT","volume":19582,"amount":4237546.7582,"timestamp":1787696558762,"change":-0.02,"changeRate":-0.000092,"amplitude":0.01079},"volumeRatio":0.688415,"impliedVol":0.2594,"impliedVolPercentile":0.8566},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","floatShares":50300000,"roa":"0.10%","roe":"24.54%","lyrEps":-1.493977,"volumeRatio":0.688415,"shares":50300000,"dividePrice":0.4038,"high":217.12,"amplitude":0.01835,"preClose":212.53,"low":213.22,"week52Low":137.09,"pbRate":"1.34","psRate":"261.88","week52High":217.12,"institutionHeld":0,"latestPrice":216.4,"committee":0.998572,"eps":6.311863,"divideRate":0.001866,"volume":1466073,"delay":0,"ttmEps":6.311863,"open":213.4,"prevYearClose":168.77,"prevWeekClose":213.56,"prevMonthClose":186.41,"prevQuarterClose":190.19,"fiveDayClose":203.56,"twentyDayClose":190.52,"sixtyDayClose":172.18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBB\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IBB","amount":0.023774,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2026-03-17","symbol":"IBB","amount":0.121818,"announcedDate":"2026-03-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-17","defaultRemindTime":1773754200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-03-17","currency":"USD","dateTimestamp":1773720000000,"payDate":"2026-03-20"},{"date":"2025-12-16","symbol":"IBB","amount":0.183099,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-09-16","symbol":"IBB","amount":0.082843,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-19"},{"date":"2025-03-18","symbol":"IBB","amount":0.121169,"announcedDate":"2025-03-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-18","defaultRemindTime":1742304600000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-21","payableDate":"2025-03-18","currency":"USD","dateTimestamp":1742270400000,"payDate":"2025-03-21"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBB\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-26","recordDate":"2016-09-28","paymentDate":"2016-09-30","value":0.0858219,"currency":"USD"},{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.091903,"currency":"USD"},{"executeDate":"2017-03-24","recordDate":"2017-03-28","paymentDate":"2017-03-30","value":0.29898,"currency":"USD"},{"executeDate":"2017-06-27","recordDate":"2017-06-29","paymentDate":"2017-06-30","value":0.176803,"currency":"USD"},{"executeDate":"2017-09-26","recordDate":"2017-09-27","paymentDate":"2017-09-29","value":0.118654,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBB\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660848445","title":"EyePoint公司治療年齡相關性眼病的藥物晚期臨床試驗失敗，股價暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848445","media":"路透中文","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848445?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:14","pubTimestamp":1786965255,"startTime":"0","endTime":"0","summary":"EyePoint公司未能证明Duravyu在保护视力方面不比Eylea明显逊色。而在接受Eylea治疗的患者中，未出现此类情况。EyePoint的股价在早盘交易中跌至4.16美元。EyePoint计划于2027年上半年向美国FDA提交批准申请，具体取决于预计于今年晚些时候公布的第二项晚期临床试验结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E0O1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2362541513.USD","BK4139","LU2089984988.USD","LU0289739699.SGD","REGN","LU0823434583.USD","LU0053666078.USD","OTLK","LU2362541273.HKD","BK4588","BK4007","IBBQ","BBH","TBXU","LU0114720955.EUR","LU2362540622.SGD","LU0882574055.USD","LU2468319806.SGD","LU0109394709.USD","EYPT","LU2237438978.USD","BK4585","LU2106854487.HKD","LU0823416689.USD","LU2023250504.SGD","LU0823434740.USD","LU0889565916.HKD","IBB","LU1974910355.USD","LU0320765992.SGD","LU1917777945.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481020","title":"美股異動 | Argenx(ARGX.US)盤前升逾10% 自身免疫性肌炎藥物Vyvgart III期研究達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660481020?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 18:48","pubTimestamp":1786963699,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4505","BK4585","IE00B4R5TH58.HKD","LU1983260115.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0889565916.HKD","IE0034235188.USD","BK4588","LU0823416689.USD","IE0002141913.USD","BK4139","ARGX","IE00BFTCPJ56.SGD","TBXU","BK4134","IE0009355771.USD","IBB","LU0320765992.SGD","LU2324357040.USD","IE00BJT1NW94.SGD","FMED","IE00B2B36J28.USD","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848605","title":"美股異動丨Argenx SE盤前大升逾7%，Efgartigimod治療肌炎III期試驗成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848605","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848605?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:37","pubTimestamp":1786959424,"startTime":"0","endTime":"0","summary":"Argenx SE(ARGX.US)盘前涨超7%，报913.38美元。消息面上，公司宣布，Efgartigimod在治疗自身免疫性肌炎的III期ALKIVIA试验中达到了主要终点。在52周时，与安慰剂相比，药物在总改善评分(TIS) 上实现了具有统计学和临床意义的改善。此次试验成功对Argenx意义重大，开辟新市场：自身免疫性肌炎在美国影响约10万人，其中IMNM约2万，DM约4万，这是一个尚未被满足的巨大医疗市场。公司计划为IMNM提交加速审批申请，并将与FDA讨论DM的申报可能性。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["TBXU","LU0889565916.HKD","LU0109394709.USD","IE00B4R5TH58.HKD","IBB","BK4588","LU0320765992.SGD","IE0002141913.USD","ARGX","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4505","LU1983260115.SGD","LU0823416689.USD","III","IE0034235188.USD","BK4585","FMED","BK4134","BK4139","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0009355771.USD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660866704","title":"復星醫藥子公司攜生物類似藥出海 牽手全球仿製藥龍頭，鎖定四成銷售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2660866704","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660866704?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:26","pubTimestamp":1786958770,"startTime":"0","endTime":"0","summary":"8月17日，复星医药（SH600196，股价24.01元，市值588.9亿元）公告披露，其控股子公司复宏汉霖与全球生物类似药龙头SandozAG于8月16日签订《合作框架协议》。双方约定，可就复宏汉霖至多10款单克隆抗体（mAb）和/或抗体偶联药物（ADC）生物类似药，开展海外区域的注册、商业化、开发、生产等许可合作，并已就首批3款产品达成具体商业条款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843260444.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843260444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","LU2272731782.SGD","BK0028","BK1515","LU1992135472.HKD","BK4585","BK0096","BK4588","LU2473716301.USD","LU2322448957.HKD","BK0183","BK0060","XPH","BK0188","IE00B5TLWC47.USD","LU2322448791.USD","BK0239","IBB","BK0012","BK0196","LU2272731600.USD","BK1593","LU2272731865.HKD","02196","600196","LU1992135399.USD","BK1191","BK0175","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660857514","title":"復宏漢霖與山德士達成戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2660857514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660857514?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:05","pubTimestamp":1786957508,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B5TLWC47.USD","LU2272731782.SGD","BK4588","LU2322448957.HKD","PPH","LU2272731600.USD","LU2272731865.HKD","BK4585","LU1992135472.HKD","IBB","LU1992135399.USD","LU2473716301.USD","LU2322448791.USD","XPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660853994","title":"argenx SE（ARGX）宣佈Efgartigimod治療自身免疫性肌炎的3期ALKIVIA試驗取得積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2660853994","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660853994?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 16:43","pubTimestamp":1786956188,"startTime":"0","endTime":"0","summary":"该试验评估了皮下注射药物VYVGART Hytrulo在成人自身免疫性肌炎中的疗效，包括免疫介导的坏死性肌病和皮肌炎。在IMNM亚组分析中，治疗组同样展现出14.8分的显著改善。这是全球首个在没有任何批准疗法的IMNM领域取得统计学显著与临床意义改善的三期临床试验。自身免疫性肌炎属于罕见且高度致残的疾病，长久以来临床严重依赖大剂量激素和广谱免疫抑制剂。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303846","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE0002141913.USD","TBXU","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU1983260115.SGD","FMED","BK4505","IE00B2B36J28.USD","IE0034235188.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4588","IE00B4R5TH58.HKD","BK4585","ARGX","LU0823416689.USD","IE00BJT1NW94.SGD","IBB","BK4139","LU2324357040.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660101358","title":"巴克萊上調安進目標價至380美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660101358","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660101358?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 11:05","pubTimestamp":1786935953,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BBH","LU1571399168.USD","LU1023059063.AUD","TBXU","BK4581","BK4139","IE00BFTCPJ56.SGD","BK4534","LU2112291526.USD","LU0109394709.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","BK4588","PJP","LU2242652126.USD","LU0868494617.USD","SG9999001440.SGD","UUP","IBB","LU0122379950.USD","BK4566","LU2089984988.USD","BK4533","UDN","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BIB","BK4585","LU1061106388.HKD","LU1983299246.USD","LU2242646821.SGD","PBE","LU0320765992.SGD","LU0058720904.USD","LU1057294990.SGD","AMGN","LU0289739699.SGD","IE0009355771.USD","BK4599","IE0002141913.USD","IBBQ","IE00BJJMRZ35.SGD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660106203","title":"復宏漢霖擬向山德士授權至多10款生物類似藥，國產生物藥國際化再進一步｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2660106203","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660106203?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 09:33","pubTimestamp":1786930438,"startTime":"0","endTime":"0","summary":"过去一周（截至8月14日收盘），创新药板块震荡上行。打包医药全产业链的医药ETF（512120）上涨0.2%，聚焦A股创新药的生物医药ETF（159508）上涨1.77%，聚焦港股创新药的港股通生物科技ETF（159102）上涨0.12%。相关个股中，康龙化成上涨8.48%、药明康德上涨2.85%、恒瑞医药下跌3.66%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173842706171.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173842706171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","LU2322448957.HKD","LU2473716301.USD","HK0000320264.USD","IBB","HK0000320223.HKD","09939","BK1161","LU2272731865.HKD","BK1515","LU1992135399.USD","LU2272731782.SGD","PPH","LU2272731600.USD","IE00B5TLWC47.USD","02696","HK0000306701.USD","BK1574","HK0000306685.HKD","LU2322448791.USD","159938","XPH","LU1992135472.HKD","159839","HK0000165453.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660110620","title":"復宏漢霖攜手Sandoz佈局生物類似藥 首批3款產品落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2660110620","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660110620?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 09:22","pubTimestamp":1786929720,"startTime":"0","endTime":"0","summary":"8月17日，复宏汉霖（02696）发布公告，公司于2026年8月16日与SandozAG达成战略合作框架协议，预计2026年可实现的开票金额总计不超过1.01亿元美元。此次合作开发最多10款单抗和/或ADC生物类似药相关产品，后续针对各个产品另行签订附属协议确定具体合作条款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173842662937.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173842662937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XPH","LU2322448957.HKD","IBB","PPH","LU2272731865.HKD","HK0000306685.HKD","HK0000306701.USD","LU2272731782.SGD","BK4585","LU1992135472.HKD","LU2272731600.USD","LU2322448791.USD","BK4588","HK0000320223.HKD","LU1992135399.USD","BK1161","02696","HK0000165453.HKD","HK0000320264.USD","LU2473716301.USD","IE00B5TLWC47.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660219103","title":"復星醫藥：控股子公司與Sandoz AG達成至多10款生物類似藥許可合作，首批3款產品首付款及里程碑款至多2.37億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660219103","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660219103?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 07:48","pubTimestamp":1786924110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2272731782.SGD","SILJ","LU2473716301.USD","LU1992135472.HKD","LU2322448791.USD","PPH","LU2322448957.HKD","LU1992135399.USD","IE00B5TLWC47.USD","BK4588","LU2272731600.USD","BK4210","AG","SLVX","LU2272731865.HKD","BK4585","SLVR","XPH","SLJY","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659400001","title":"Assembly股價上漲，因季度營收超出預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2659400001","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659400001?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 23:25","pubTimestamp":1786721141,"startTime":"0","endTime":"0","summary":"BUZZ-Assembly股价上涨，因季度营收超出预期8月14日-** 药物研发公司Assembly Biosciences（ASMB.O）股价上涨4.6%，报31.32美元** ASMB第二季度与吉利德（GILD.O）合作研究的收入为1340万美元，高于去年同期的960万美元** 据LSEG数据显示，分析师此前平均预期营收为860万美元** 公司表示，营收增长包括针对吉利德合作项目下未来活动最新预估所作的510万美元补足调整** 报告显示第二季度每股亏损20美分，而市场预期为每股亏损65美分** 计入当日涨幅后，该股年初至今累计上涨11.8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL4S44B103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","IE00BSNM7G36.USD","BK4566","LU0234570918.USD","BK4585","LU2468319806.SGD","SG9999015986.USD","BK4532","IE00B3T34201.USD","LU0861579265.USD","TBXU","LU1934455277.USD","SG9999015952.SGD","LU0058720904.USD","LU0965508806.USD","LU1061106388.HKD","GILD","LU1839511570.USD","LU2087621335.USD","LU2324357040.USD","TMED","BIB","BMED","IE00B19Z3581.USD","LU0889565916.HKD","LU1066051498.USD","BBH","SG9999015945.SGD","IBBQ","LU0122379950.USD","LU0965509101.SGD","IE00B19Z3B42.SGD","BK4588","BK4578","LU0965509283.SGD","LU1037948541.HKD","LU0114720955.EUR","MEDI","LU1585245621.USD","LU0289739699.SGD","LU0109394709.USD","IE00BZ1G4Q59.USD","BK4139","BK4550","IBB","BK4568","LU1037948897.HKD","ASMB","LU2112291526.USD","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中國銀河證券：實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","LFSC","601881","APXH","SBIO","XLVI","BBP","BIOY","BK0276","BK1147","BK1564","GSKH","BK0188","IBB","06881","BK4585","PBE","BK4588","GDOC","WRND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["APXH","IBB","GSKH","600721","BK0102","BK4585","GDOC","BIOY","BK0216","PBE","LFSC","SBIO","XLVI","WRND","BK4588","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658465479","title":"MacroGenics股價上漲，因吉利德支付了1000萬美元的里程碑款項","url":"https://stock-news.laohu8.com/highlight/detail?id=2658465479","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658465479?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 05:18","pubTimestamp":1786483082,"startTime":"0","endTime":"0","summary":"BUZZ-MacroGenics股价上涨，因吉利德支付了1000万美元的里程碑款项8月11日-** 药物开发商MacroGenics（MGNX.O）的股价在盘后交易中上涨3.8%，至4.07美元** 该公司表示，根据其与吉利德（GILD.O）就一项临床前双特异性项目（一种癌症疗法）达成的许可协议，已收到1000万美元的里程碑付款** 根据2022年签署的合作协议，MacroGenics与吉利德正在推进三个项目：处于临床阶段的抗癌疗法MGD024，以及两个处于临床前阶段的双特异性项目** MGNX仍有资格获得最高约16亿美元的额外开发、监管及商业里程碑付款** 今年以来，该公司股价已翻了一番多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S4481IH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","SG9999015952.SGD","LU1674673691.USD","LU1674673428.USD","LU1023059063.AUD","SG9999015986.USD","LU0058720904.USD","SG9999015945.SGD","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU2087621335.USD","LU1585245621.USD","IBBQ","LU0882574055.USD","LU1778281490.HKD","LU2468319806.SGD","MEDI","IE00BSNM7G36.USD","LU1430594728.SGD","BK4585","BK4550","BK4588","LU1934455863.HKD","LU0289739699.SGD","LU1066051498.USD","IE00BZ1G4Q59.USD","BK4578","SG9999015978.USD","BMED","MGNX","IE00B7SZLL34.SGD","LU2089984988.USD","LU0114720955.EUR","BK4532","TBXU","BBH","LU0965508806.USD","LU1934455277.USD","BK4139","IBB","GILD","IE00B19Z3B42.SGD","LU0965509101.SGD","TMED","LU0234570918.USD","LU1839511570.USD","BIB","LU1571399168.USD","IE0002270589.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658591102","title":"數據簡報-全球製藥企業斥資數十億以擴大在美業務","url":"https://stock-news.laohu8.com/highlight/detail?id=2658591102","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658591102?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 23:59","pubTimestamp":1786463961,"startTime":"0","endTime":"0","summary":"数据简报-全球制药企业斥资数十亿以扩大在美业务更新了第18段中关于百健生产工厂的数据路透8月11日-全球制药企业正扩大在美国的业务布局，承诺投入数十亿美元以提升该国的生产能力和研发实力。该公司于6月表示，已在佛罗里达州杰克逊维尔投资约10亿美元，以加强其眼科护理业务在美国的制造能力。这家制药公司宣布将投资 6.5 亿美元 ，以扩大其位于波多黎各洪科斯工厂的药品生产规模，此举预计将创造近 750 个就业岗位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S448167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014880.SGD","LU0234570918.USD","LU0823434583.USD","LU1699723380.USD","GILD","LU2360106947.USD","LU0965509101.SGD","LU1551013425.SGD","LU2106854487.HKD","BMY","LU0265550359.USD","LU0225771236.USD","LU2271345857.HKD","LLYZ","LU1585245621.USD","MEDI","LU0130517989.USD","LU0820561818.USD","LU2430703095.HKD","LU2357627491.SGD","IE00B7KXQ091.USD","LU1894683264.USD","LU1244550221.USD","LU1829250122.USD","LU2361044865.SGD","LU1244550577.SGD","LU1221951129.SGD","LU0109394709.USD","LU0426412945.USD","SGXZ81514606.USD","XLV","GLAM","IE00B19Z3581.USD","LU2089984988.USD","LU0211328371.USD","LU0786609619.USD","LU1941712264.USD","LU0203345920.USD","LU2168564222.USD","LU0158827781.USD","LU2264538146.SGD","LU1883839398.USD","SGXZ51526630.SGD","IE00B3T34201.USD","LU2347655073.USD","IE00B1BXHZ80.USD","LU2403377893.USD","IE000MB6IJN5.SGD","IE00BFTCPJ56.SGD","LU1244550494.USD","LU1868837136.USD","LU0672654240.SGD","IBB","LU2360032135.SGD","IE00BVYPNV92.GBP","LU2237443465.HKD","LU1839511570.USD","LU1261432733.SGD","LU2236285917.USD","IE00BVYPNW00.USD","ELIS","LU0795875086.SGD","VHT","LU2552382215.SGD","LU0820562030.AUD","LU1066051811.HKD","AMGN","LU1267930573.SGD","LU0471298694.HKD","LU1228905037.USD","LU1023059063.AUD","IE000M9KFDE8.USD","LU2471134796.USD","TBXU","BK4588","LU0345769128.USD","LU1069344957.HKD","LU1868836757.USD","LU1366192091.USD","LU0122379950.USD","LU2756315318.SGD","LU0289739699.SGD","LU0072461881.USD","THNR","BK4007","LU1629891620.HKD","LU0820561909.HKD","IE00BN8TJ469.HKD","IE00BZ1G4Q59.USD","LU0211327993.USD","LU0354030438.USD","LU0980610538.SGD","LU0708995401.HKD","LU2361045086.USD","LU2023250330.USD","LU1814569148.SGD","LU0985481810.HKD","JDOC","TMED","LU0912757837.SGD","LU1043141123.HKD","LU1934455194.USD","LU0787776722.HKD","BK7067","LU2756315664.SGD","IE00BJJMRY28.SGD","FHLC","LU0106261372.USD","MEDX","LU1116320901.HKD","LU0061475181.USD","LU0942090050.USD","LU1804176565.USD","PPH","PAWZ","BK4550","LU0053666078.USD","LU0471298777.SGD","LU0234572021.USD","LU0306806265.USD","LU0964807845.USD","LU1061106388.HKD","LU0320765992.SGD","LU2471134879.HKD","SG9999001176.SGD","IE00BJLML261.HKD","LU2491050154.USD","SG9999015945.SGD","BK4566","BK4585","LU0109391861.USD","SG9999014914.USD","AZNH","LU1035773651.USD","LU0237698245.USD","LU1670627923.USD","ILDR","LU2125154935.USD","LU0353189680.USD","LU0225284248.USD","LU0889566641.SGD","BK4599","BK7508","LU1267930490.SGD","IE00BKVL7J92.USD","LU0889565916.HKD","SG9999003800.SGD","LU1623119135.USD","GB00BDT5M118.USD","SG9999018865.SGD","LU0170899867.USD","AGNG","LU0097036916.USD","LU1127390331.HKD","LU0006306889.USD","LU2023250504.SGD","LU0133085943.USD","LU0238689110.USD","IE0005OL40V9.USD","LU2112291526.USD","LU2125909247.SGD","LU0395794307.EUR","LU1032955483.USD","LU0316494557.USD","LU0321505868.SGD","LU1121112475.USD","LU2125154778.USD","LU1032466523.USD","IE00B4JS1V06.HKD","IE000F7OJYX1.SGD","LU1506573853.SGD","LU2168564495.EUR","LU2361044949.HKD","LU0689626769.HKD","LU0553294199.USD","LU0661504455.SGD","LU2468319806.SGD","LU2417539215.USD","LU0114720955.EUR","LU1914381329.SGD","CANC","IE000BZT7R73.USD","LU2023251221.USD","IE00BLSP4452.SGD","LU1917777945.USD","LU1720051108.HKD","LU1280957306.USD","LU1035775433.USD","LU2462157665.USD","LU0094547139.USD","SG9999014559.SGD","LU1196500208.SGD","LU0689472784.USD","LU1670711040.USD","BBH","LU2028103732.USD","LU2471134952.CNY","LU2133065610.SGD","LU0070302665.USD","LU0861579265.USD","RXL","LU0994945656.USD","SG9999014575.USD","IE000SO60NU8.SGD","IE00B42XCP33.USD","LU0203347892.USD","PFE","LU2129689514.USD","HRTS","LU1037948897.HKD","LU2063271972.USD","LU1934455277.USD","LU0868494708.USD","LU1934455863.HKD","LU1894683348.USD","IE0004445239.USD","IE00BFSS8Q28.SGD","LU1720051017.SGD","LU2746668974.SGD","LU2211815571.USD","LU2242652126.USD","IE0034235303.USD","IE0002141913.USD","LU1074936037.SGD","LU2456880835.USD","LU2462591350.SGD","LU2461242641.AUD","LU0198837287.USD","LU1003077747.HKD","ABBV","IE00BBT3K403.USD","LU1064131342.USD","SG9999015978.USD","SG9999014567.USD","BIB","IE00B19Z3B42.SGD","LU0511384066.AUD","LU0882574055.USD","BK4504","LU0058720904.USD","LU2168564149.EUR","IE00B3PB1722.GBP","LU0726765562.USD","LU2487616109.SGD","LU2552382132.HKD","LU1221951046.USD","LU2505996681.GBP","LU1116320737.USD","LU1430594728.SGD","LU0225283273.USD","SGXZ80539844.SGD","IE0004445015.USD","LU2087621335.USD","LU1868836914.USD","SG9999015341.SGD","LU2089283258.USD","LU0057025933.USD","LU0320765646.SGD","CSL.AU","LU1670711123.USD","LU2168564065.EUR","LU2237443549.SGD","LU2265009873.SGD","LU1201861249.SGD","LU2237443622.USD","LU0823434740.USD","LU2242646821.SGD","LU0162691827.USD","LLY","LU0321505439.SGD","LU1232071149.USD","LU2237443978.SGD","LU1983299246.USD","IE00BJJMRZ35.SGD","LU0965509283.SGD","LU1548497426.USD","SG9999013999.USD","LU0466842654.USD","LU1778281490.HKD","LU1929549753.HKD","LU2750360997.AUD","CURE","SG9999015358.SGD","LU1670628061.USD","LU0354030511.USD","BK4532","IE00BK4W5M84.HKD","LU2324357040.USD","LU0708994859.HKD","LU1868837300.USD","LU1043141396.HKD","SG9999015952.SGD","LU1496350171.SGD","LU1974910355.USD","BK4568","LU1941712348.USD","LU2237443382.USD","LU1496350502.SGD","LU0965508806.USD","LU0859254822.USD","BK4139","LU1057294990.SGD","LU2213496289.HKD","LU0868494617.USD","LU2129689605.HKD","LU1059921491.USD","LU0128525929.USD","WDNA","LU0985320562.USD","LU1267930730.SGD","IE000WAW04H5.SGD","PJP","IE00B775H168.HKD","LU1162221912.USD","LU1674673428.USD","LU2602419157.SGD","LU0158827948.USD","LU1868836591.USD","IE00BJJMRX11.SGD","LU0472753341.HKD","LU2357305700.SGD","BK7511","LU0545562505.USD","FTXH","04332","LU1989772840.SGD","LU2592432038.USD","LU0345769631.USD","LU0882574139.USD","MRK","SG9999015986.USD","SG9999011175.SGD","IE00BWXC8680.SGD","LU0417517546.SGD","LU0130102774.USD","LU1267930813.SGD","LU2505996509.AUD","BMED","LU0289961442.SGD","LU0070217475.USD","IBBQ","LU1066051225.USD","BK7501","BK4592","SG9999014542.SGD","SG9999018857.SGD","IE00B4R5TH58.HKD","BK4583","IHE","LU2552382058.USD","LU1988902786.USD","LU1923622614.USD","SGXZ57979304.SGD","LU1732800096.USD","LU0266013472.USD","LU0174119429.USD","SG9999014898.SGD","LU1551013342.USD","LU1935042991.SGD","LU0545039389.USD","BK4559","IE00BFXG1179.USD","BK4578","LU1989771016.USD","IE00B894F039.SGD","LU1323610961.USD","LU0098860793.USD","LU2129689431.USD","IE0001KFT4U8.USD","BK4534","IE00BGHQF631.EUR","IE00B2B36J28.USD","LU1732799900.SGD","LU1571399168.USD","IE0000B7K699.USD","LU1712237335.SGD","SG9999001176.USD","LU1037948541.HKD","LU1228905540.USD","IE00BKDWB100.SGD","JNJ","IE00B19Z9P08.USD","LU1066051498.USD","LU2237443895.HKD","LU0210528500.USD","SG9999002224.SGD","LU2237438978.USD","ELIL","IE00BN29S564.USD","LU0683600562.USD","LU1670710588.SGD","LU0965509010.AUD","LU0256863902.USD","LU0823416689.USD","IE0002270589.USD","LU0203201768.USD","LU0320765489.SGD","LU0323591593.USD","LU1979441026.SGD","PBE","IE00BDGV0183.EUR","LU2125909593.SGD","LU1066053197.SGD","LU2087625088.SGD","LU0432979614.USD","LU0306807586.USD","BK4581","LU1291159041.SGD","LLII","IE00BSNM7G36.USD","LU0096364046.USD","SGXZ31699556.SGD","LU2168563687.JPY","LU2433249047.HKD","LLYX","LU1718418525.SGD","LU0267386448.USD","BK4516","IE00BK4W5L77.USD","MHIP","LU0345770308.USD","LU2896262040.SGD","LU0069063385.USD","IE00BKPKM429.USD","LU1145028129.USD","LU0256863811.USD","LU1093756168.USD","LU2491049909.HKD","LU0795875169.SGD","LU2023250843.SGD","LU2750360641.GBP","LU0648001328.SGD","LU2491050071.SGD","LU2108987350.USD","IE00B19Z9Z06.USD","IXJ","LU0345770993.USD","LU2089284900.SGD","LU2596442595.SGD","LU0943347566.SGD","IE00BFSS7M15.SGD","LU1674673691.USD","LU2430703251.USD","LU1093756325.SGD","LU2471134523.USD","SG9999017495.SGD","LU0310799852.SGD","TRUH","SGXZ99366536.SGD","IE00B1XK9C88.USD","LU0265550946.USD","LU0289739343.SGD","LU0477156953.USD","SG9999002232.USD","BIIB","LU0211331839.USD","LU0792757196.USD","BK4533","LU2111349929.HKD","LU0456855351.SGD","SG9999001440.SGD","LU0738911758.USD","LU1989772923.USD","IE00BLSP4239.USD","IYH","IE00BJT1NW94.SGD","AZN","LU0208291251.USD","LU2430703178.SGD","LU0426417589.USD","LU2347655156.SGD","LU0640476718.USD","LU0310800379.SGD","LU0385154629.USD","LU0353189763.USD","LU0124676726.USD","LU1069347547.HKD","LU0029864427.USD","IE0009355771.USD","LU1670710661.SGD","GDOC","OZEM","SG9999014906.USD","LU0320765059.SGD","LU2746668461.USD","LU0079474960.USD","LU0949170772.SGD","LU0203202063.USD","LU0210536198.USD","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658391156","title":"Tango因季度虧損額超出預期而股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2658391156","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658391156?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 23:19","pubTimestamp":1786461555,"startTime":"0","endTime":"0","summary":"BUZZ-Tango因季度亏损额超出预期而股价下跌8月11日-** 药物研发公司Tango TherapeuticsTNGX.O股价下跌3.3%，报26.75美元** 据LSEG数据显示，该公司报告第二季度每股亏损37美分，而分析师平均预期为每股亏损31美分** TNGX报告称，截至2026年6月30日的三个月内未产生合作收入，原因是与吉利德GILD.O的合作关系及研发活动已终止** 该公司202","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4T44814U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1934455863.HKD","IE00B19Z3581.USD","LU1674673691.USD","RVMD","IBB","LU0889565916.HKD","LU0289739699.SGD","LU0109394709.USD","LU0114720955.EUR","LU2089984988.USD","IE0009355771.USD","SG9999015952.SGD","IE0002270589.USD","TBXU","LU1934455277.USD","BK4532","LU0965508806.USD","BIB","IBBQ","IE00B2B36J28.USD","MEDI","BK4583","BMED","BBH","LU1778281490.HKD","LU1066051498.USD","PTH","IE00B7SZLL34.SGD","LU0320765992.SGD","LU2468319806.SGD","BK4585","IDNA","LU1674673428.USD","LU2324357040.USD","LU1066053197.SGD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","TNGX","IE00B4R5TH58.HKD","LU1037948897.HKD","LU2087621335.USD","TMED","LU0861579265.USD","BK4588","LU0965509010.AUD","CANC","LU0234570918.USD","GILD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GDOC","WRND","BIOY","SBIO","PBE","APXH","IBB","LFSC","BK4585","XLVI","BBP","GSKH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK0216","IBB","XLVI","WRND","GSKH","BBP","BK0102","APXH","LFSC","GDOC","BIOY","PBE","SBIO","BK4585","600721"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"東方證券：AI重構創新藥研發底座 國內相關產業鏈公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1147","BK0188","600958","SBIO","GDOC","BK4588","BK0028","ARTY","BK0183","BK0012","IBB","BIOY","XLVI","AIPO","AGIX","VTHR","BK1564","CHAT","BK4585","PBE","03958","WRND","QTOC","APXH","LFSC","GSKH","BK0276","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196566","title":"百濟神州（06160）盤初漲3.94% 與安進聯合開發及商業化的安泰適正式投入臨床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196566","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658196566?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 09:39","pubTimestamp":1786412383,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 盘初上涨3.94%，最新报221.60港元，成交额1.86亿港元。消息面上，百济神州8月11日早上宣布，由百济神州与安进公司共同负责在中国开发和商业化的安泰适正式投入临床使用。此外，8月10日，百济神州宣布与Revolution Medicines达成一项多方面合作协议。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987884","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE0009355771.USD","688235","IE00BJT1NW94.SGD","TBXU","LU1983299246.USD","LU2242652126.USD","BBH","IBBQ","LU1061106388.HKD","LU0122379950.USD","BK1583","BK4533","LU2242646821.SGD","AMGN","BK1588","SG9999001440.SGD","BK1500","LU0307460666.USD","06160","IE0002141913.USD","LU0228659784.USD","IBB","BK4585","KURE","LU1057294990.SGD","LU2112291526.USD","BK4526","PBE","BK1161","BK4139","ONC","LU2089984988.USD","LU0289739699.SGD","IE00B2B36J28.USD","BIB","IE00B4R5TH58.HKD","LU1571399168.USD","PJP","LU0058720904.USD","LU1770034418.SGD","LU2468319806.SGD","BK4588","LU0109394709.USD","BK4534","LU0828237510.HKD","LU0588546209.SGD","BK4599","LU1969619763.USD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":2,"totalSize":150,"code":"91000000","status":"200"}]}}